Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

/PRNewswire/ -- Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an...

Related Keywords

United States ,China ,London ,City Of ,United Kingdom ,Tobias Arkenau ,Rajan Jethwa ,Christopher Evans ,Ellipses Pharma ,Global Head Of Drug Development ,Drug Administration End Of Phase ,Pharma Limited Ellipses ,Drug Administration ,Pharma Limited ,Ellipses Phase ,Sichuan Kelun Biotech ,Modular Phase ,Orphan Drug Designation ,Fast Track Designation ,Sir Christopher Evans ,Chief Executive Officer ,Global Head ,Drug Development ,Chief Medical Officer ,National Medicinal Products Administration ,Kelun Pharmaceutical ,